Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
HAMPTON, N.J., Sept. 23, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 2:00 p.m. EDT in New York.
The live webcast will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
